International Journal of Clinical and Experimental Pathology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Clinical study of the combined use of dexmedetomidine and remifentanil in patients with coronary heart disease undergoing 3D laparoscopic surgery with EEG bispectral index monitoring
CONCLUSION: In patients with coronary heart disease undergoing 3D laparoscopic surgery, the intraoperative use of Dex combined with Rem anesthesia offers several advantages. It helps stabilize hemodynamics, reducing the risk of myocardial ischemia, and significantly alleviates postoperative pain, all without increasing the likelihood of adverse postoperative reactions. Furthermore, this approach effectively dampens the intraoperative and postoperative stress response, facilitating enhanced recovery after surgery (ERAS). Overall, the clinical impact is positive, safe, and reliable.PMID:38188350 | PMC:PMC10767478 (Source: In...
Source: International Journal of Clinical and Experimental Pathology - January 8, 2024 Category: Pathology Authors: Shiqi Diao Dongxin Wang Ying Chang Chunyan Ni Dongmei Fu Jixin Liu Song Gao Xiunan Jia Tongrao Wang Xi Nan Hongling Cao Zongming Liu Xitong Zhang Source Type: research
Peutz Jeghers syndrome accompanied with cervical gastric adenocarcinoma and extensive metastasis: a case report
We reported a patient with a case of PJS with a lower abdominal mass as the clinical manifestation. Physical and auxiliary examinations showed a large pelvic and abdominal mass. According to the patient's PJS history, gastric adenocarcinoma (GAC) was diagnosed after timely cervical biopsy. The patient underwent abdominal and pelvic mass resection and extensive hysterectomy. The tumor extensively disseminated to the bilateral ovaries, endometrium, fallopian tubes and pelvis. The cyclin-dependent kinase inhibitor 2A gene mutation was demonstrated in cervical GAC samples using next-generation sequencing. We summarized the lit...
Source: International Journal of Clinical and Experimental Pathology - January 8, 2024 Category: Pathology Authors: Xia Wu Dongni Liang Ying He Source Type: research
Association between p73 RS2273953 to RS1801173 polymorphism and risk of lung cancer: a meta-analysis of 2,897 cases and 3,317 controls
CONCLUSIONS: Our analysis suggested a lack of association between p73 RS2273953 to RS1801173 polymorphism and risk of lung cancer overall. However, patients with GC/GC polymorphism showed an increased risk for squamous carcinoma in the lung compared to those with GC/AT+AT/AT in Asians.PMID:38188352 | PMC:PMC10767479 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - January 8, 2024 Category: Pathology Authors: Xu Li Zaiqiang Guo Chengwei Zhang Ying Xiong Chunxia Ding Ke Wei Xiaohong Dai Hui Dai Yonghuai Ma Fangcai Lin Source Type: research
Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research
EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research
Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma
CONCLUSION: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.PMID:38059173 | PMC:PMC10695748 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Zhangfu Li Jiangbei Yuan Zilong Yan Xu Liu Jikui Liu Source Type: research
Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. eCollection 2023.ABSTRACTLenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant s...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Xinlin Yu Chun Wei Ran Cui Ou Jiang Source Type: research
Bilateral and synchronous male breast cancer: a case report
Int J Clin Exp Pathol. 2023 Nov 15;16(11):352-356. eCollection 2023.ABSTRACTGenetic mutational characterization of synchronous bilateral male breast cancer (BC) has been poorly reported due to its rarity. Herein, we present a 55-year-old male patient who was diagnosed with bilateral breast cancer (BBC) and harbored different gene mutations. The diagnosis of synchronous bilateral breast cancer (SBBC) was made using ultrasonography, magnetic resonance imaging (MRI), mammography and core-needle biopsy. Subsequently, bilateral modified radical mastectomies were performed, and histopathologic examination revealed invasive ducta...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Shaoqiang Zhou Jiankui Wang Ming Li Yinju Yang Hushan Zhang Dedian Chen Source Type: research
Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research
EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research
Long noncoding RNA LINC00665 is a diagnostic biomarker that enhances cell proliferation and migration in hepatocellular carcinoma
CONCLUSION: LINC00665 was upregulated in HCC tissues and cells and might be used to predict a poor prognosis of HCC patients. In addition, LINC00665 may promote the malignant progression of HCC by enhancing proliferation and migration capacities.PMID:38059173 | PMC:PMC10695748 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Zhangfu Li Jiangbei Yuan Zilong Yan Xu Liu Jikui Liu Source Type: research
Lenvatinib plus Immune Checkpoint Inhibitors versus Lenvatinib monotherapy as treatment for advanced hepatocellular carcinoma: a meta-analysis
Int J Clin Exp Pathol. 2023 Nov 15;16(11):321-331. eCollection 2023.ABSTRACTLenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless, findings from the Leap-002 study suggest that the addition of anti-vascular drugs to Lenvatinib may not yield significant improvements in survival rate. This meta-analysis aims to comprehensively assess the effectiveness of Lenvatinib, both as a standalone treatment and in combination with immune checkpoint inhibitors (ICIs), in managing advanced aHCC patients. We retrieved relevant s...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Xinlin Yu Chun Wei Ran Cui Ou Jiang Source Type: research
Bilateral and synchronous male breast cancer: a case report
Int J Clin Exp Pathol. 2023 Nov 15;16(11):352-356. eCollection 2023.ABSTRACTGenetic mutational characterization of synchronous bilateral male breast cancer (BC) has been poorly reported due to its rarity. Herein, we present a 55-year-old male patient who was diagnosed with bilateral breast cancer (BBC) and harbored different gene mutations. The diagnosis of synchronous bilateral breast cancer (SBBC) was made using ultrasonography, magnetic resonance imaging (MRI), mammography and core-needle biopsy. Subsequently, bilateral modified radical mastectomies were performed, and histopathologic examination revealed invasive ducta...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Shaoqiang Zhou Jiankui Wang Ming Li Yinju Yang Hushan Zhang Dedian Chen Source Type: research
Pathogenesis and treatment progress in age-related hearing loss: a literature review
Int J Clin Exp Pathol. 2023 Nov 15;16(11):315-320. eCollection 2023.ABSTRACTAge-related hearing loss (ARHL) is a progressive sensorineural hearing loss caused by age. The pathogenesis of ARHL is not completely clear at present, but it is closely related to auditory nerve degeneration, metabolic disorders, vitamin deficiency, and genetics, especially mitochondrial DNA damage. With the acceleration of industrialization and urbanization in our country, the impact of environmental noise is increasing, and ARHL has become one of the most important factors affecting the quality of life of the elderly in our country. Therefore, h...
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Jianghui Yang Zhangtao Shao Duomi Zhang Kai Wang Source Type: research
EHD2, a novel HIF target gene, is a promising biomarker in clear cell renal cell carcinoma
CONCLUSION: EHD2 is a novel HIF target, based on a relatively large sample of EHD2 research in patients with ccRCC. Furthermore, our study provided evidence that EHD2 can serve as a promising biomarker for predicting ccRCC outcome.PMID:38059172 | PMC:PMC10695750 (Source: International Journal of Clinical and Experimental Pathology)
Source: International Journal of Clinical and Experimental Pathology - December 7, 2023 Category: Pathology Authors: Yufeng Chen Song Xue Jian Shi Chunfeng He Qingchuan Zhang Source Type: research
